Literature DB >> 65432

Primary in vitro antibody response from human peripheral blood lymphocytes.

J F Delfraissy, P Galanaud, J Dormont, C Wallon.   

Abstract

A method for the induction of a primary in vitro antibody response from human peripheral blood lymphocytes is presented. Upon cultivation with trinitrophenyl conjugated polyacrylamide beads (TNP-PAA), an anti-TNP response can be obtained as indicated by the appearance of direct plaque-forming cells from day 5 of culture, with a reproducible peak on day 8. These plaques correspond to cells actively producing antibody of the IgM type, as shown by their inhibition by cycloheximide and by anti-human IgM serum, but not by anti-human Fc gamma serum. Their specificity for the TNP hapten can be demonstrated by the effector cell blockade phenomenon, with highly substituted TNP-human IgG. Although the anti-TNP response induced by TNP-PAA in mouse spleen cell cultures appears T independent the same response in human PBL may involve in addition the participation of T cells, since E-RFC depletion before culture led to a markedly decreased number of plaque-forming cells. A significant response could be obtained from the PBL of all of the 30 normal individuals tested. Importantly, the response was reproducible in its magnitude in the six individuals tested in at least three different experiments. Thus, the in vitro stimulation of human PBL by TNP-PAA can be proposed as a reliable test for the study of human B cell function in a specific primary antibody response.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 65432

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Depressed primary in vitro antibody response in rheumatoid arthritis.

Authors:  P Segond; J F Delfraissy; P Galanaud; C Wallon; P Massias; J Dormont
Journal:  Clin Exp Immunol       Date:  1979-08       Impact factor: 4.330

2.  Immunoregulation in humans: control of antitetanus toxoid antibody production after booster immunization.

Authors:  R H Stevens; A Saxon
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

3.  Regulation of the primary in vitro antibody response in human peripheral blood lymphocytes: different effects of mitogen-induced and spontaneous T suppressor cells.

Authors:  P Galanaud; M C Crevon; J F Delfraissy; P Segond; C Wallon; J Dormont
Journal:  Clin Exp Immunol       Date:  1979-10       Impact factor: 4.330

4.  Impaired primary in-vitro antibody response in progressive systemic sclerosis patients: rôle of suppressor monocytes.

Authors:  P Segond; D Salliere; P Galanaud; R M Desmottes; P Massias; J N Fiessinger
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

5.  Age-related impairment of the in vitro antibody response in the human.

Authors:  J F Delfraissy; P Galanaud; J Dormont; C Wallon
Journal:  Clin Exp Immunol       Date:  1980-01       Impact factor: 4.330

Review 6.  In vitro antibody response of human lymphocytes.

Authors:  C J Heijnen; F UytdeHaag; R E Ballieux
Journal:  Springer Semin Immunopathol       Date:  1980-05

7.  Use of a human plaque-forming cell assay to study peripheral blood bursa-equivalent cell activation and excessive suppressor cell activity in humoral immunodeficiency.

Authors:  H G Herrod; R H Buckley
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

8.  Human anti-tetanus antibody response in vitro: autologous and allogeneic T cells provide help by different routes.

Authors:  M K Brenner; A J Munro
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

9.  Antigen-induced in vitro antibody production in humans: a model for B cell activation and immunoregulation.

Authors:  D J Volkman; H C Lane; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

10.  Differential effects of azathioprine on T cells regulating murine B-cell function.

Authors:  H Duclos; M C Maillot; P Galanaud
Journal:  Immunology       Date:  1982-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.